Genomic medicine has already changed oncology, what it has not changed is access. Today, sequencing a patient’s DNA and identifying clinically meaningful mutations is technically possible, scientifically validated, and commercially available.  Yet it remains slow, … Continue reading Rewriting the Economics of Genomics Through Minos (Bittensor Subnet 107)